DDInter458 DDInter342
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Cyclosporine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDK5R1
CDK5R1 {u} (Gene) is upregulated by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDK5R1
CDK5R1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDK5R1
CDK5R1 {u} (Gene) is downregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Gastrointestinal pain {u} (Side Effect) is caused by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Cyclosporine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Ganciclovir
Ganciclovir {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Cyclosporine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Cyclosporine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Cyclosporine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cyclosporine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cyclosporine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cyclosporine (Compound) downregulates CDK5R1 (Gene) and CDK5R1 (Gene) is upregulated by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cyclosporine (Compound) downregulates CDK5R1 (Gene) and CDK5R1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may lead to a major life threatening interaction when taken with Certolizumab pegol
Cyclosporine (Compound) downregulates CDK5R1 (Gene) and CDK5R1 (Gene) is downregulated by Mycophenolic acid (Compound) and Mycophenolic acid may lead to a major life threatening interaction when taken with Certolizumab pegol
Cyclosporine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cyclosporine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ganciclovir (Compound) and Ganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol